Companies / PHX

PHARMX TECHNOLOGIES LIMITED

ASX:PHXSoftware & Services
666.1M shares on issueASX (delayed) · as of 28 July 2026$0.11price · delayed$73.3Mmarket cap · indicative
B
Dilution grade

Share count grew 11% in 24 months; 1 cash raise in 24 months

Cash runwayno data — not a quarterly (4C/5B) cash filer
Share-count growth (24m)11.1%
Raise cadence (24m)1 cash raise
Options & rights overhang4.0% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

PHARMX TECHNOLOGIES LIMITED's ordinary share count grew 11.1% between October 2025 and July 2026, to 666M shares. The company raised capital once in the 24-month window, a placement on February 2026 that produced A$9.7M in proceeds, and total proceeds in that period are A$9.7M. Options and rights on issue could convert into 26M new shares, equal to 4.0% of the current share count, of which 0% are in the money. The company does not have a current quarterly cash report on record, so no quarterly cash balance or funding-runway figure is disclosed. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
4.0%
Max option dilution
0.0%
ITM option dilution
1
Raises · last 12 months
—
Cash cover · not a quarterly filer

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 666.1M per ASX (delayed) (28 July 2026).
612.7M632.3M651.9MDec 24Sept 25July 26Cash raise · 23 Feb 2026

Cash runway

Not a quarterly cash filer. This company does not lodge Appendix 4C/5B quarterly cash reports, so cash runway does not apply.

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
10 July 20262A · quoted issuePHX : ORDINARY FULLY PAID666.1MAppendix 2A
26 Feb 20262A · quoted issuePHX : ORDINARY FULLY PAID659.5MAppendix 2A
7 Oct 20253H · cancellationPHX : ORDINARY FULLY PAID598.5MAppendix 3H
7 Oct 20253G · unquotedORDINARY FULLY PAID598.5MAppendix 3G
7 Oct 20253H · cancellationPHX : ORDINARY FULLY PAID598.5MAppendix 3H
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

1 cash raise in the last 24 months · 1 in the last 12 months

$9.7M
Placement
23 Feb 2026 COMPLETE
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

4.0%
Total overhang · of current shares
0.0%
In the money · at current price
26.5M
Potential new shares
—
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

No director dealing notices (Appendix 3Y) on record.
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

10 July 2026Cleansing Notice
10 July 2026Application for quotation of securities - PHX
10 July 2026Sigma Healthcare 10% strategic holding now complete
6 July 2026Pharmx Renews National NDSS Agreement
28 June 2026Agreement of first work item under Sigma Strategic Alliance
16 June 2026Notice of Investor Presentation
5 May 2026Q3 Investor Update FY2026
13 Mar 2026Initial Director's Interest Notice - M Conway
13 Mar 2026Director Appointment
11 Mar 2026Becoming a substantial holder
26 Feb 2026Cleansing Notice
26 Feb 2026Application for quotation of securities - PHX
24 Feb 2026$PH1 FY26 Investor Presentation
24 Feb 2026$PH1 FY26 Results Announcement
24 Feb 2026$PHalf Yearly Reports & Accounts
22 Feb 2026Proposed issue of securities - PHX
22 Feb 2026$PPharmx and Sigma enter multi-year strategic alliance
3 Feb 2026Notice of Results Announcement - 31 December 2025
11 Nov 2025Results of Annual General Meeting
10 Nov 2025Chairman's Address & CEO Presentation

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.